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ABSTRACT 
Herpes zoster (HZ) or Shingles is often followed by Post Herpetic Neuralgia (PHN). 
PHN is a chronic pain condition usually occurring a few months after the visible 
symptoms of HZ subside. Although Testosterone can affect pain responses, the role of 
testosterone in PHNs is unknown. Testosterone is converted into estrogen in certain 
areas including the thalamus of the brain by the enzyme aromatase. We tested our 
hypothesis that testosterone conversion to estrogen in thalamus attenuates HZ induced 
pain. 
Male Sprague-Dawley rats were divided into control and virus groups receiving 
whisker pad injections of either MeWo cells or MeWo cells containing varicella Zoster 
Virus (VZV), respectively. Virus injections (100 µl) were in the left whisker pad and 
contained either 60,000 pfu of virus or control. Virus and control  groups were further 
divided in two drug groups receiving the aromatase inhibitor letrozole or the vehicle 
dimethyl sulfoxide (DMSO). Drug was given either locally or systemically. Guide 
cannulas were placed in the thalamic area for a portion of the rats using stereotaxic 
coordinates for local administration of drug. The conversion of testosterone into estrogen 
is selectively inhibited using Letrozole. The motivational and affective aspect of 
nociception was measured using Place Escape Avoidance Paradigm (PEAP) assay.  
Measurements were completed once a week for three weeks.
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Data obtained were statistically analyzed and demonstrated that virus 
injection significantly increased the nociceptive response compared to the control. This 
nociceptive response was significantly increased after administration of Letrozole. 
In conclusion, testosterone reduces the VZV associated nociceptive response, in part, 
due to conversion into estrogen in the thalamic region. 
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1. INTRODUCTION
The varicella zoster virus (VZV) causes Herpes Zoster (HZ). The Virus affects 
humans in early age causing chicken pox and thereafter it remains latent in sensory  
nerve ganglia (Mahalingam et al. 1992). The virus gets reactivated mostly in elderly and 
immunocompromised patients and triggers HZ also known as Shingles (Donahue et al. 
1995; Jung et al. 2004). It is one of the common neurological disorders in the USA, with 
almost a million of reported incidences annually (Donahue et al. 1995; Johnson et al. 
2015). The Advisory Committee on Immunization Practices mentioned in their report 
that one in every three persons develops HZ during their lifetime (Harpaz et al. 2008). In 
spite of immunity due to vaccination, about 20% of patients develop PHN. The increased 
load of Medicare costs is another major concern (Brisson et al. 2001; Donahue et al. 
1995; Johnson et al. 2015; Johnson et al. 2010). Although HZ incidence increases after 
50 years of age, it can affect all ages (Civen et al. 2009). The clinical presentation of 
VZV infection usually involves neuronal inflammation, blisters and dermatomal rash 
causing severe itching (Cohen 2013). This outbreak of shingles is also associated with 
pain which is often observed during an early phase of HZ and then abates. The pain then 
often returns few months (>3 months) after the episode of HZ, can be chronic and is 
called post- herpetic neuralgia (PHN). PHN is considered as a potential complication of 
HZ with inflammation and nerve damage (Friesen et al. 2017). The pain distribution is 
along  one  or  more  sensory nerve  roots  after  the  HZ  (Soares  and  Provenzale 2016). 
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Often, variation of this time scale is noted (Hadley et al. 2016; Johnson and Higa 2012). 
This pain can severely affect the quality of life of the patient suffering with PHN 
(Johnson et al. 2010). 
The thalamus has an active role in orofacial nociceptive responses (de Leeuw et 
al. 2005; Sessle 1986; Yen and Lu 2013). Lesions of the thalamus increase nociceptive 
response (Saade et al. 1999). Orofacial nociception modulation by sex steroids has been 
an area of interest for quite some time. These steroids are derivatives of the steroid 
hormone family with cholesterol being its precursor (Amandusson and Blomqvist 2013). 
Gender differences in pain has been attributed to sex- specific neurobiological 
mechanisms, differences in reproductive circuitry and behavior (Craft et al. 2004). 
Modulation of pain sensitivity by steroids, especially estradiol, has been widely studied 
(Aloisi and Sorda 2011; Amandusson and Blomqvist 2013; Craft 2007; Craft et al. 2004; 
Palmeira et al. 2011; Pieretti et al. 2016). These neurosteroids influence the excitability 
of neurons, particularly by acting on neurotransmitter. (Balthazart and Ball 2000; 
Beyenburg et al. 2001; Mellon 1994). The ovaries are the primary source of estrogen but 
it can also be found in fat, muscles, testes and the brain. 
Aromatase inhibitors are well known for their effectiveness in treatment of breast 
cancer in postmenopausal women. They act my inhibiting the synthesis of estradiol 
(Dowsett et al. 1995). Patients undergoing the aromatase inhibitor therapy often 
discontinued their treatment due development complaint of pain in their joints and/or 
muscles (Henry et al. 2012; Henry et al. 2008). Robarge et al, suggested estrogen to be 
negative regulator of pain with references to many studies where estrogen was shown to 
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have antinociceptive effects (Robarge et al. 2016). In the brain, enzyme aromatase 
catalyzes the synthesis of estrogen from androgens (Amandusson and Blomqvist 2013). 
Aromatase is present in different brain regions in different proportions. High levels of 
aromatase activity are seen in regions with high estradiol levels (Konkle and McCarthy 
2011). Although this distribution was similar in males and females; males showed a 
higher number of aromatase mRNA expressing cells than females (Stoffel-Wagner 
2003). In humans, aromatase mRNA levels are found to be highest in the thalamus, 
pons, hypothalamus and hippocampus (Azcoitia et al. 2011; Sasano et al. 1998). Within 
the central nervous system, the modulation of nociception occurs in the presence of 
locally produced estrogen by aromatization of testosterone (Evrard 2006; Evrard and 
Balthazart 2004; Hau et al. 2004). Genes controlling nociception are increased in the 
thalamus when estrogen levels are elevated (Umorin et al. 2016). 
Blockade of aromatase with the use of aromatase inhibitors increases the 
nociceptive responses in rats (Ghorbanpoor et al. 2014; Robarge et al. 2016). To study 
chronic VZV induced orofacial PHN male rats were given Letrozole, a third-generation 
aromatase inhibitor and nociception was measured. The male Sprague Dawley rats were 
given letrozole either systemically and or directly into the thalamus using chronically 
bilaterally placed guide cannulas and then orofacial induced VZV PHN nociception was 
measured. 
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2. MATERIAL AND METHODS
2.1 Animal Husbandry 
The protocol was approved by Texas A&M University College of Dentistry 
Institutional Animal Use Committee. Adult male Sprague-Dawley rats (280-300g) from 
Harlan Industries, Houston, Texas were kept on a 12:12 light/dark cycle. The rats were 
given food and water ad libitum. Rats in a first experiment were divided so that half 
received an injection of VZV and half received control. These animals were further 
divided so that half received a subcutaneous injection of letrozole and half received 
vehicle thus, the groups were control/vehicle, control/letrozole, VZV/vehicle, 
VZV/letrozole. Rats in a second experiment underwent surgery to place a bilateral guide 
cannula into the thalamus and were divided so that half received an injection of VZV 
and half received control. These animals were further divided so that half received 
letrozole infusion and half received vehicle thus, the groups were control/vehicle, 
control/letrozole, VZV/vehicle, VZV/letrozole. After a four-day acclimation period 
surgeries were performed. After a four-day acclimation period surgeries were performed. 
2.2 Surgery 
After the acclimation period 28 rats (300-350 grams) were anesthetized with 2% 
isoflurane with an airflow of 2 liters per minute. Using sterile technique guide cannulas 
(C313G Plastics One, Roanoke, VA) were placed bilaterally into the thalamus 
stereotaxically using the coordinates 3.6 mm posterior of Bregma, 2.8 mm from midline 
at a depth of 5.5mm from dura. The guide cannulas were closed with obturators. Post- 
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surgery the animals were given nalbuphine (2mg/kg) subcutaneously. This dose of 
analgesic was repeated once again after 24 hours and the animals were allowed to 
recover for a week. 
2.3 Behavioral Testing 
One week after thalamic injections were complete the rats were anesthetized 
briefly with 2% isoflurane using a 2 liter per minute flow of air and the left whisker pad 
was injected with 100 µl of MeWo cells infected with VZV or control MeWo cells 
lacking virus. After a week, post-surgery, animals from both groups were further divided 
into two groups, Virus (VZV) and Control (MeWo) group. Left whisker pad of VZV 
animals were injected with 100 µl of high concentration MeWo cells (human skin cell 
line) infected with VZV (>60,000 pfu/µl) and the control group received MeWo cells 
lacking virus. The measurement of infectious virus particles is quantified by plaque 
forming units (pfu). 
In the cannulated group one week after whisker pad injections, the VZV injected 
group and the MeWo injected groups were sub-divided and half received bilateral 
thalamic infusions of either letrozole dissolved in Dimethyl Sulfoxide (DMSO) or only 
DMSO (vehicle). At the time of infusions, the obturators were removed and an injection 
syringe was inserted. Bilateral infusions (0.05 µl/min) were made of letrozole (500 µl at 
a concentration of 5 mg/ml) or DMSO (500 µl). Bilateral infusions were made to avoid 
any bias in the results seen in right thalamus because of the use of letrozole. After 
infusion,  the injector cannula  was  left in  place  for 5 minutes,  then removed  and   the 
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obturator replaced. The letrozole infusions were done a day (24 hours) prior and again 
four hours before behavioral testing. The Systemic group was subdivided and one 
subgroup was injected subcutaneously with (500 µl to reach a dose of 5 mg/kg) letrozole 
and the control subgroup with DMSO (500 µl). The injections were given a day (24 
hours) prior and again four hours before behavioral testing. 
Place Escape/Avoidance Paradigm (PEAP) testing was performed to determine 
nociception. To accomplish this the rats were placed in a 30 cm X 30 cm X 30 cm  
acrylic box where half the box was covered in black cloth. This test chamber was 
modeled from the PEAP test performed by the Fuchs’s laboratory (LaBuda and Fuchs 
2000). This assay is used to measure the affective aspect of nociception in neuropathic 
models (Baastrup et al. 2011; LaBuda and Fuchs 2000). The PEAP test is based on the 
assumption that if animals escape and/or avoid a noxious stimulus, then the stimulus is 
aversive to the animal (Fuchs and McNabb 2012). PEAP has been used in both 
inflammatory and neuropathic nociception models with rats of both sexes and with 
various strains and ages as a means of measuring the affective aspect of nociception. 
Rodents being nocturnal in nature preferred to stay on the dark side when placed into the 
test chamber that has a light and dark side. After placing the rat in the test chamber, it 
was immediately poked with a 60-gram filament every 15 seconds on the injected side if 
the rat was on the dark side and on the non-injected side if it was on the light side. The 
target region for the poking was the area below the eye and caudal to the whisker pad. 
This region is innervated by the second branch of trigeminal nerve (DaSilva and 
DosSantos 2012), the nerve infected by VZV injection of the whisker pad. Sensitivity  of 
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the face around the eye was expected. Pokes were performed in the region below the eye 
and caudal to the whisker pad, a region innervated by the second branch of the trigeminal 
ganglia. The time spent on the dark side of the box was recorded in 5-minute bins and 
testing was performed for a total of 30 minutes. Testing was performed once a week. 
Testing was completed for 2 weeks in both groups. Thus, the theory behind the test is 
that if the rat is experiencing VZV induced nociception when poked in the sensitive area 
it will not stay on it preferred dark side but will move to the non-preferred light side and 
stay there is avoid the nociceptive poke. 
2.4 Tissue Collection 
The cannulated animals were sacrificed in the second week within 1 hour post 
PEAP testing. 4 animals from each of the four groups VZV-Letrozole, VZV-DMSO, 
MeWo-Letrozole and MeWo-DMSO were randomly selected and were sacrificed by 
exposure to CO2 followed by decapitation. The brain was removed using a rongeur and 
sliced on a slicer with 1 mm increments (Zivic, Pittsburgh, PA). Sections were made to 
be 2 mm thick by skipping every other slot in the slicer and the sections between 
Bregma -3 to -5 were placed on glass slides and kept on dry ice. Lateral thalamic tissue 
was collected with punches 2 mm in diameter centered on the injection site. Punches 
included the posterior nucleus, ventral posteromedial, ventral posterolateral and reticular 
thalamic nuclei termed the lateral thalamus. Tissue was stored in liquid nitrogen until 
RNA could be isolated. 
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2.5 Real Time PCR 
RNA extraction was performed using the RNA Lipid Tissue Kit from Qiagen 
(Valencia, CA). The RNA concentration in the resulting sample was determined on a 
Nanodrop2000. A one-step reverse transcription PCR reaction was performed on 
BioRAD C1000 Thermal Cycler using the SYBR-Green 1-Step RT-PCR kit and primers 
from Qiagen (Table 1). The thermal protocol was 30 min @ 50 °C for the reverse 
transcription reaction, 15 min @ 95 °C for DNA pol activation and 40x (15 s @ 94 °C 
melting, 30 s @ 56 °C annealing, 30 s @ 72 °C extension). A melting curve was obtained 
thereafter for quality assurance. The sample amount was adjusted according to total RNA 
concentration to obtain 20 ng of total RNA per well in the final reaction mix. All 
reactions were run in triplicate. PCR runs that did not exhibit a proper amplification 
profile were discarded. 
9 
Table 1. PCR primer pairs for RT-PCR 
Gene Qiagen Catalog # Qiagen ID 
GAPDH QT00199633 Gapd 
GPR30 QT00376943 Gper1 
Estrogen receptor alpha QT00369740 ESrra 
Estrogen receptor beta QTOO190113 Esr2 
Aromatase receptor QT01812433 Ar 
Aromatase enzyme QT00186942 Cyp19a1 
VGAT QT00378413 Viaat 
2.6 Immuno-fluorescent Staining 
Three animals from each of the four groups were randomly selected for 
immuno- fluorescent staining to see the neuronal activity around the infusion site. After 
anesthesia with 100 mg/kg ketamine and 10 mg/kg xylazine the animals were perfused 
with 9% sucrose followed by 4% paraformaldehyde. Fixed tissues were stored in 25% 
sucrose, frozen, cryo-sectioned and the 20 µm sections placed on Histobond slides 
(VWR international, Radnor, PA). The tissue was then blocked with a PBS solution 
containing 5% normal goat serum (Sigma-Aldrich, St. Louis, MO) and 0.3% Triton-X 
100 for 2 hours at room temperature. The slides were then incubated in a primary 
antibody solution overnight at 4°C. The primary antibody consisted of a mixture of the 
mouse monoclonal NeuN antibody (neuron marker) and mouse monoclonal pERK 
antibody (phosphorylated extracellular signal-regulated kinase) (neuron activity 
marker) at 1:400 
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dilution (Millipore, Billerica, MA). The primary antibody was diluted with PBS, 5% 
BSA and 0.3% Triton X-100. After incubation in primary antibody the slides were then 
rinsed three times in PBS and Triton-X 100 for a total of 45 min and placed for 2 hours 
in secondary antibody and PBS and 0.3% Triton X-100. Secondary antibodies included a 
mixture of goat anti-rabbit 568 or goat anti-mouse 488 (Invitrogen, Carlsbad, CA). 
After rinsing the slides three times in PBS for a total of 45 min, the slides were mounted 
with Fluoromount-G mounting medium containing Hoechst 33342 stain (Electron 
Microscopy Sciences, Hatfield, PA). The fluorescent signal was imaged using a Nikon 
fluorescent microscope and NIS-Elements imaging software and a Photometrics CoolSnap 
K4 CCD camera (Roper Scientific, Inc, Duluth, GA). 
2.7 Statistics 
Data was analyzed with ANOVA because of the repeated measurements and 
multiple groups and the independent variable was the PEAP data and the dependent 
variables were virus and drug. When a significant effect was observed Bonferroni post- 
hoc tests were completed (Prizm 5.04, GraphPad Software, La Jolla, CA, or Abstat, 
Anderson Bell Corp, Arvada CO). 
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3. RESULTS
3.1 PEAP Testing 
PEAP test was completed beginning a week after whisker pad VZV or control 
injections. Fewer seconds on the dark side indicates a greater affective nociception 
response (LaBuda and Fuchs 2000). 
Figure 1. Week 1 PEAP data of systemic group. 
3.2 Systemic Injection Groups 
PEAP data from the systemic drug treated group (Fig.1) shows that in the 1st 
week the animals which received virus, whether given letrozole or its vehicle spent  
much less time on the dark side compared to the controls. Animals in the control group 
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remained in the dark side almost throughout the testing period. When comparing the 
virus group injected with vehicle to the virus group injected with letrozole a significant 
main effect for letrozole was observed (p<0.001). No significant difference was 
calculated when comparing the control/vehicle and control/letrozole groups. Two weeks 
after injecting the whisker pad (Fig.2) rats followed the same pattern as in week 1. VZV 
treated groups had a greater level of nociception while the controls showed no 
nociceptive response (p<0.001). The virus group injected with vehicle had less of a 
nociceptive response compared to the virus group injected with letrozole (p<0.01). 
However, the animals in VZV vehicle group showed a decreased nociception response 
compared to the first week. The control response in Week 2 was similar to their response 
in Week 1. 
Figure 2. Week 2 PEAP data of systemic group (n=6 per group) 
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Figure 3. Week 1 PEAP data of cannulated group. The symbols # and * indicate a 
significant difference between the indicated groups (p<0.05), n=8 per group. 
During Week 1 animals which received virus, whether given letrozole or vehicle 
spent significantly less time on the dark side compared to the controls (Fig. 3). The 
control animals infused with letrozole spent significantly less time on the dark side when 
compared to the VZV rats infused with letrozole (Fig. 3). This difference was significant 
at all-time points (5, 10, 15, 20, 25 and 30 minutes). For control and virus groups 
receiving vehicle, a significant difference was observed in the 25-minute bin (Fig. 3). 
Within the virus group there was a significant difference observed between animals that 
received letrozole and those that received vehicle (10,15,20,25 and 30 min). Animals   in 
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the control injected letrozole infused group spent most of their time on the dark side as 
did the control injected vehicle infused group; there was no significant difference 
between these groups. 
Figure 4. Week 2 PEAP assay data of Cannulated group. The symbols # and * indicate a 
significant difference between the indicated groups (p<0.05), n=8 per group. 
In the second week animals in the virus/vehicle and virus/letrozole group 
continued to show an increased nociceptive response (Fig. 4). The rats in the 
VZV/letrozole group spent the least amount of time on the dark side. The difference was 
significant between virus and control group receiving letrozole at all the time points of 
PEAP testing (Fig. 4). Significant differences were also observed between control and 
virus group receiving vehicle at all time points of PEAP testing except at first    5-minute 
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point. Similarly, a significant difference in the nociceptive response was also observed 
within the virus groups receiving vehicle or letrozole at all time points of PEAP testing 
except at the first 5-minute mark. The non-virus (control) injected groups spent almost  
all their on the dark side. 
3.3 Thalamus Cannulated Group Summary 
The animals which received virus injections showed a greater nociceptive 
response and spent most of the time on the light side. Non-virus (control) injected 
animals showed no nociceptive response and stayed on the dark side almost throughout 
the testing period. Within the virus group the animals that received letrozole showed a 
significantly greater nociceptive response compared to the animals that received vehicle. 
3.4 Thalamus Gene Analysis 
Gene transcripts with potential to have a role in testosterone and estradiol 
regulated pathways were quantitated within the thalamic tissue. These genes included  
the estradiol receptors ERα and ERβ, as well as, the membrane estradiol receptor GPR30 
(Table 1). The aromatase enzyme that converts estradiol to testosterone was analyzed 
(Table 1). Testosterone can bind to the aromatase receptor to cause changes in pain 
responses and thus, was analyzed at the transcript level (Fischer et al. 2009; Fischer et al. 
2007). VGAT is known to regulate pain responses and has been shown to be regulated  
by estradiol thus, this gene was analyzed by RT-PCR (Kramer and Bellinger 2009; 
Kramer et al. 2015). The analysis was completed using RT-PCR and was normalized 
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against the values of GAPDH to get a expression value (delta-Ct). The delta-Ct values of 
the genes were plotted on the Y-axis to represent the relative change in expression for 
each of the transcripts (Fig. 5 and 6). The gene expression levels for the aromatase gene 
did not show any difference with the use of letrozole (Fig. 5 and 6). Similar to aromatase 
gene expression levels, androgen and estrogen receptor levels did not show any 
significant difference with the use of letrozole. The gene expression level of VGAT was 
significantly (p<0.05) elevated with the letrozole treatment in both the right and left 
thalamus (Fig. 5 and 6). 
Figure 5. Gene Expression in Left Thalamus 
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Figure 6. Gene Expression in Right Thalamus 
3.5 Immunostaining 
Neuronal nuclei (NeuN) positive cells were present in the thalamic area around 
the infusion site (Fig.7). NeuN is a neuronal marker. Cells in the same area were also 
positive for phosphorylated extracellular signal-regulated kinase (pERK) (Fig.8). pERK 
is a good marker for nociception-induced neuronal activation (Gao and Ji 2009). 
Activated neurons were present adjacent to the cannulation site where infusion of 
letrozole was performed (Fig. 9). Quantitation of these neurons and correlation of these 
cell counts to virus and drug treatment would allow for analysis of the role of thalamic 
neurons in the nociceptive response. For example, if the thalamus has a role in the 
nociceptive response we would expect an increase in activated neurons in virus infected 
animals.  Moreover, if letrozole increased the number of activated     neurons  this  result 
18 
would suggest that the increased nociceptive response due to letrozole included a 
mechanism localized to the thalamus. 
Figure 7. NeuN positive neurons (green) 
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Figure 8. pERK positive neurons (red) 
Figure 9. Merged double staining image showing neuronal activity. 
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4. DISCUSSION
VZV injection into the whisker pad results in a nociceptive response in the facial 
region. The response for the PEAP assay was significant for the first two weeks. The 
results from the third week were not significant (data not included). We believe that a 
reduced response in the third week may be due to the decreasing effect of virus. As seen 
from the behavioral data letrozole administration increased the VZV associated 
nociceptive response. The animals in the VZV/letrozole group spent the least amount of 
time on the dark side. The results from the PEAP assay for both systemic and cannulated 
groups show that letrozole administration significantly increased the VZV associated 
nociceptive response compared to the vehicle animals receiving DMSO. This 
demonstrated that inhibition of the aromatase enzyme does have an effect on the 
modulation of the nociception, consistent with the findings from previous studies  
(Evrard 2006; Ghorbanpoor et al. 2014). From the graphs, some difference is seen 
between the results from the systemic and cannulated groups. We believe the increased 
response to nociception in the cannulated group when compared to the systemic group 
might be due to the surgeries done during cannula placements. 
Previous studies have suggested that estradiol attenuates nociception. The gene 
expression for vesicular GABA transporter (VGAT) increases in thalamus when  
estradiol levels are elevated. Previous studies from our lab suggested thalamic  
expression of VGAT modulates nociception in the orofacial region (Kramer and 
Bellinger 2009; Kramer et al. 2015). Letrozole was infused in both the right and left 
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thalamus and we expected to see a decrease in the thalamic VGAT expression as 
compared to the vehicle treated groups because letrozole administration would decrease 
estradiol levels. However, the results from RT-PCR experiments demonstrated that 
letrozole treatment increased VGAT transcript in both the right and left thalamus as 
compared to the controls. If the reduced VGAT were affecting the nociceptive response, 
we should have seen a decrease in the nociceptive response upon letrozole treatment but 
we saw an increase instead suggesting that modulation of nociceptive response was not 
likely due to changes in VGAT expression. Further studies looking at protein levels are 
needed to verify this conclusion. We believe there might be some other factors which 
might be playing active role in modulation of nociception other than VGAT. One such 
mechanism for nociceptive modulation would be the effect of estrogen on glutamate 
levels. Estrogen has been shown to modulate nociception by decreasing glutamate levels 
in thalamus. Further studies are required to properly explain this phenomenon. In some 
studies estrogen has been shown to facilitate nociceptive transmission via membrane 
bound estrogen receptors (Zhang et al. 2012). 17β-estradiol, the most potent form of 
estrogen, has been shown to regulate gene expression of voltage gated sodium channels 
acting via estrogen receptors alpha and beta which may play a vital role in modulation of 
nociception (Hu et al. 2012). Thus, estrogen can modulate nociception acting through 
any of its receptors in a genomic or non-genomic way (Amandusson and Blomqvist 
2013; Craft 2007; Deliu et al. 2012). We looked at the expression levels for androgen 
and estrogen receptors. There was no change in expression levels of these receptors after 
letrozole  administration.  Moreover, the receptor  expression for aromatase also  did  not 
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show any difference due to virus or drug. These results are consistent with the idea that 
letrozole does not have any effect on the expression of these receptors and that these 
receptors might not function in the modulation of VZV associated. 
In summary, after the administration of letrozole the animals in the virus group 
showed a greater response to nociception as compared to the ones receiving DMSO 
(vehicle) or control groups without virus. Inhibiting the activity of aromatase increased 
the nociceptive response in virus group suggesting testosterone might be attenuating the 
nociceptive response by its aromatization to estradiol. 
23 
5. CONCLUSION
Our behavioral results indicate that testosterone attenuated the VZV associated 
nociceptive response after conversion to estradiol suggesting that in humans, pain 
conditions attenuated by testosterone may actually be modulated by androgens being 
converted to estradiol rather than being effected by testosterone directly 
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